23

Listed companies

8

Private companies

41

Insiders

Relation chart of related listed companies: Mount Magnet South Ltd

Active Relations

Past Relations

Relationship chart for related private companies: Mount Magnet South Ltd

Active Relations

Past Relations

Related private companies: Mount Magnet South Ltd

Australasian Institute of Mining & Metallurgy

Miscellaneous Commercial Services

Australian Institute of Geoscientists

Miscellaneous Commercial Services

The Institute of Chartered Accountants in Australia

Institute of Chartered Secretaries & Administrators (AU)

Stichting Sanammad

Investment Trusts/Mutual Funds

Governance Institute of Australia Ltd.

Miscellaneous Commercial Services

Sanammad Pharmaceuticals BV

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Other Metals/Minerals10
Precious Metals6
Miscellaneous Commercial Services5
Investment Trusts/Mutual Funds1
Chemicals: Agricultural1
Internet Software/Services1
Miscellaneous1
Aerospace & Defense1
Integrated Oil1
Pharmaceuticals: Other1

Countries of related companies

Australia28
Netherlands2
Canada1
Logo Mount Magnet South Ltd
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Employees
-